Clearside Biomedical, Inc.
Clearside Biomedical, Inc. (CLSD) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
clsd · stock forecast · 8 analysts (3M) · FMP · updated Mar 18, 2026
Analyst Rating & Consensus
Based on 8 Wall Street analysts in the past 3 months
Buy
8 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $0.30
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $0.30 | ↑ 0.00% |
1-day model range: $0.3–$0.3. Peak: $0.3 (+0.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · CLSD · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-11-18 | Needham | Maintains | Hold→Hold |
| 2025-07-18 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2025-07-18 | Chardan Capital | Downgrade ↓ | Buy→Neutral |
| 2025-07-17 | Needham | Downgrade ↓ | Buy→Hold |
| 2025-05-23 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-05-16 | JMP Securities | Maintains | Market Outperform→Market Outperform |
| 2025-05-15 | Needham | Maintains | Buy→Buy |
| 2025-04-08 | Needham | Maintains | Buy→Buy |
| 2025-03-31 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-28 | Citizens Capital Markets | Maintains | Market Outperform→Market Outperform |
Wall Street analysts have recently issued updated ratings on Clearside Biomedical, Inc. (CLSD) stock. Of the recent 52 rating actions, 2 were upgrades and 3 were downgrades. 8 analysts currently cover CLSD.
Analyst Recommendation Trends
CLSD analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 3 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$3M
↓ 81.3% YoY
Revenue Next Year
$7M
↑ 141.6% YoY
EPS This Year
$-4.65
EPS Next Year
$-3.30
↓ 29.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast CLSD EPS of $-4.65 for the current fiscal year, based on estimates from 3 analysts. The CLSD revenue forecast is $3M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CLSD stock forecast is supported by two independent data sources: analyst consensus ratings from 8 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CLSD price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The CLSD short-term stock prediction for tomorrow is $0.30 (+0.00%).
Clearside Biomedical, Inc. trades on NASDAQ under the ticker CLSD. The CLSD stock outlook for 2027 is broadly positive, supported by a Buy consensus among 63% of covering analysts.
Frequently asked questions
CLSD forecast · 8 questionsAccording to 8 Wall Street analysts, the average 12-month CLSD price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $0.30.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.